Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Status:
Terminated
Trial end date:
2016-06-23
Target enrollment:
Participant gender:
Summary
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral
T-cell lymphoma who are candidates for autologous stem cell transplants.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Eisai Inc. Roswell Park Cancer Institute University of Chicago University of North Carolina Wake Forest School of Medicine Washington University Early Recognition Center Washington University School of Medicine Weill Medical College of Cornell University